Indirect Impact of the COVID-19 Pandemic on Hospitalisations For Cardiometabolic Conditions and Their Management: A Systematic Review

SAMUEL SEIDU (✉ sis11@le.ac.uk)

University of Leicester <https://orcid.org/0000-0002-8335-7018>

Kunutsor SK

University of Bristol

Xavier Cos

Institut Català de la Salut: Institut Catala De La Salut

K. Khunti

University of Leicester

Original investigation

Keywords: COVID-19, impact, hospitalisation, diabetes, acute coronary syndrome, stroke cardiovascular disease, systematic review

Posted Date: May 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-501010/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: The Coronavirus disease 2019 (COVID-19) pandemic has led to a dramatic crisis in health care systems worldwide. These may have significant implications for the management of cardiometabolic diseases. We conducted a systematic review of published evidence to assess the indirect impact of the COVID-19 pandemic on hospitalisations for cardiovascular diseases and their management.

Methods: Studies that evaluated volume of hospitalisations for cardiometabolic conditions and their management with comparisons between the COVID-19 and pre-COVID periods were identified from MEDLINE, Embase and the reference list of relevant studies from January 2020 to 25 February 2021.

Results: We identified 103 observational studies, with most studies assessing hospitalisations for acute cardiovascular conditions such as acute coronary syndrome, ischemic strokes and heart failure. About 89% of studies reported a decline in hospitalisations during the pandemic compared to pre-pandemic times, with reductions ranging from 20.2 to 73%. Severe presentation, less utilization of cardiovascular procedures, and longer patient- and healthcare-related delays were common during the pandemic. Most studies reported shorter length of hospital stay during the pandemic than before the pandemic (1-8 vs 2-12 days) or no difference in length of stay. Most studies reported no change in in-hospital mortality among hospitalised patients.

Conclusion: Routine and ongoing clinical care of patients for acute cardiovascular conditions, their management and outcomes have been adversely impacted by the COVID-19 pandemic. Patients should be educated via population-wide approaches on the need for timely medical contact and health systems should put strategies in place to provide timely care to patients at high risk.

Introduction

Coronavirus disease 2019 (COVID-19), a respiratory infectious disease caused severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), was declared a global public health emergency on 30 January 2020 and it has since caused so much morbidity and mortality (1). The COVID-19 virus spreads primarily through droplets generated when an infected person coughs or sneezes, or through droplets of saliva or discharge from the nose. The majority of patients with COVID-19 are asymptomatic or exhibit mild symptoms and never require hospitalisation (2), with a few progressing to severe illness with extrapulmonary manifestations, leading to multiorgan failure and death (3-6). Accumulating evidence suggests that older and obese patients, males, Black, Asian and Minority Ethnic groups and those with pre-existing comorbidities such as cardiovascular disease (CVD), hypertension, chronic kidney and liver diseases and diabetes are more likely to be infected with SARS CoV-2 and are at highest risk for severe illness or death from COVID-19 (7-9).

Several public health response strategies have been introduced to prevent or slow down the transmission of COVID-19 and these include social distancing, quarantine, use of personal protective equipment, and personal hygiene. Since the World Health Organization (WHO) declared COVID-19 a pandemic on 12 March 2020, other strategies introduced to mitigate the spread of the virus have included shutting down entire cities or communities ("lockdowns") and banning international or domestic travel. During the period of March 2020, most countries all over the world announced nationwide lockdowns, which severely restricted movement among citizens, though people were still allowed to leave their homes for essential reasons, including seeking medical care.

The COVID-19 pandemic has led to a dramatic crisis of health care systems worldwide directly or indirectly. In pre-pandemic times, large proportions of health service budgets of countries were spent treating chronic health conditions such as CVD, diabetes and their complications. With the pandemic, large proportions of health budgets have been earmarked for COVID-19 management. Healthcare systems have also reorganised their management pathways for acute cardiovascular conditions such as stroke and acute coronary syndromes (ACSs). In addition, the social isolation measures put in place have led to losses in employment and income (9), with changes in human behaviour, including being house-bound and physically inactive because of fear of contracting the virus. All these factors are likely to increase the incidence of cardiometabolic conditions, cause delays in seeking medical care and also adversely affect in-hospital management of these patients. However, a comprehensive synthesis of the evidence of these likely trends is non-existent.

In this context, using a systematic review of all available published observational evidence, our primary aim was to assess the indirect impact of COVID-19 on hospitalisations (including emergency room attendance) and management for cardiovascular conditions. Our specific objectives were to (i) assess the different cardiometabolic conditions that have been impacted by the COVID-19 pandemic; (ii) assess prevalence and trends in hospitalisations for these cardiovascular conditions as a result of the COVID-19 pandemic; (iii) assess COVID-19 related reasons provided by patients for delaying medical contact; and (iv) assess if in-hospital management of these patients has been affected. We also sought to explore if there are gaps in the existing evidence.

Methods

Eligibility criteria

The review was conducted based on a predefined protocol and in accordance with PRISMA and MOOSE guidelines (10, 11) (**Appendix 1-2**). The protocol has been registered in the PROSPERO prospective register of systematic reviews (CRD42021236102). We searched for clinical observational studies (prospective cohort, retrospective cohort, case-cohort, nested case-control, case-control and cross-sectional) that have evaluated the indirect impact of COVID-19 on hospitalisations (including emergency room attendances) for cardiovascular diseases and management of these conditions. We included studies that reported comparisons between the COVID-19 pandemic period vs. pre-pandemic and/or historical periods (or other comparisons such as lockdown vs pre-lockdown and/or pre-COVID-19 periods; post-pandemic declaration vs pre-pandemic declaration; or in temporal relation to COVID-19 related restrictions). Henceforth, this is referred to as pandemic vs. pre-pandemic period. Cardiovascular conditions included myocardial infarction (MI), ACS (ST-elevation MI (STEMI), non-ST segment elevation MI (NSTEMI) or angina), stroke and acute heart failure (HF); hypertension; venous thromboembolism (VTE); diabetes and related complications; and mortality. The following exclusions were applied: (i) randomised control trials (RCTs) and case-control studies because patients in these study designs are selected; (ii) studies in which patients were selected and matched between the pandemic and pre-pandemic periods; (iii) studies that

had evaluated the direct effects of COVID-19 on cardiovascular conditions and their related complications; and (iv) studies with no pre-pandemic controls for comparison or did not evaluate outcomes in temporal relation to COVID-19 related restrictions.

Data sources and search strategy

We searched MEDLINE and Embase from January 2020 to 25 February 2021. The computer-based searches combined free and MeSH search terms related to impact (e.g., “impact”, “effect”, “delay”, “reduction”), COVID-19 (e.g., “COVID-19”, “SARS-CoV-2”) and cardiometabolic condition (e.g., “diabetes”, “myocardial infarction”, “acute coronary syndrome”, “cardiac arrest”, “stroke”, “heart failure”). There were no restrictions on language. Titles and abstracts of retrieved citations were initially screened by one author (SKK) to assess their suitability for potential inclusion, followed by the acquisition of full texts for detailed evaluation. Full-text evaluation was independently conducted by two authors (SKK and SS). Reference lists of retrieved articles were manually scanned for all relevant additional studies and review articles missed by the original search. Citing references were also checked in Web of Science. Full details on the search strategy are presented in **Appendix 3**.

Data extraction and risk of bias assessment

One author (S.K.K.) independently extracted data and performed risk of bias assessments using a standardized predesigned data collection form. A second reviewer (S.S.) checked extracted data with that in the original articles. Data were extracted on publication year, study design, geographical location, pandemic and pre-pandemic periods evaluated, baseline age, proportion of males, cardiometabolic condition and/or related complication, number of hospitalisations for outcome during pandemic and pre-pandemic periods or similar frame, trends in the number of hospitalisations, severity of presentation on hospitalisation, in-hospital management, patient- and system-related delays, COVID-19 related reasons provided for delaying medical contact, length of hospital stay, and outcomes related to in-hospital management. Methodological quality of observational cohort studies was assessed using the nine-star Newcastle–Ottawa Scale (NOS)(12), which uses pre-defined criteria namely: selection (population representativeness), comparability (adjustment for confounders), and ascertainment of outcome. Nine points on the NOS reflects the highest study quality. For cross-sectional studies, methodological quality was evaluated using the NOS modified for cross-sectional studies (13) (**Appendix 4**). It uses three pre-defined domains namely: selection of participants (population representativeness), comparability (adjustment for confounders), and ascertainment of outcomes of interest. A maximum score of 8 reflected the highest study quality.

Data synthesis

Where possible and appropriate, percentages were calculated $[(n/N)*100]$, where n denotes number of a particular condition and N refers to the total number of conditions. Pooled analysis could not be conducted for any of the outcomes because of the heterogeneous nature of the data. All studies reported trends in hospitalisations and provided data on outcomes, so these were summarised in tables and narrative synthesis was performed.

Results

Study identification and selection

Figure 1 shows the flow of studies through the review. The literature search identified 1,495 potentially relevant citations. After the initial screen based on titles and abstracts, 107 articles were selected for full text evaluation. Following detailed assessment of the full articles, 4 were excluded because (i) was based on a study protocol (n=1); (ii) based on selected patients (n=1); (iii) was a duplicate study (n=1); and (iv) was based on an online survey (n=1). The remaining 103 articles met the inclusion criteria and were included in the review (**Appendix 5**).

Study characteristics and study quality

Table 1 summarises the key baseline characteristics of the included studies. Most studies were published in 2020, with only 8.7% in 2021. Studies were conducted across 6 continents: 56 in Europe; 25 in North America; 13 in Asia; 3 in South America and 2 each in North America and Oceania. One study was conducted in 17 countries across 4 continents and one in 4 countries across 3 continents. Most studies were retrospective cohort designs (n=78), followed by cross-sectional designs (n=15), prospective cohort designs (n=9) and one ecological retrospective study. Sources of data were healthcare institutions/centres, registries and established databases. Except for one, all studies reported data for a period during the pandemic (ranging from January to October 2020) and compared this to data in the pre-pandemic period (ranging from October 2019 to March 2020) and/or a historical period (similar periods ranging from 2014 to 2019) or compared lockdown with pre-lockdown data based on date of lockdown in the particular country of the study. In the study by Metzler and colleagues, (14) data was collected from 2-29 March 2020 and comparisons were made between the first and last week of the period surveyed. For studies that provided data on age, mean age of patients ranged from 49 to 78 years and the mean ages were similar comparing patients between the pandemic and pre-pandemic periods. The percentage of males also appeared to be similar across both periods. Among the observational cohort studies, quality score using NOS ranged from 5 to 8 and that for the cross-sectional studies ranged from 4 to 6 (**Table 1**).

Cardiovascular diseases

Table 2 provides details of various cardiovascular diseases that were assessed by eligible studies and specific outcomes reported. The majority of studies (n=65) assessed hospitalisations for ACS (STEMI, NSTEMI or both) only, ACS patients undergoing percutaneous coronary intervention (PCI) or a combination of ACS and other cardiovascular conditions such as HF, strokes. Other outcomes assessed were stroke hospitalisations (n=30); acute HF (n=5); cardiometabolic conditions such as hypertension, diabetes, VTE and arrhythmias (n=2) and CVD deaths (n=1).

Trends in hospitalisations for cardiovascular diseases

Trends in hospitalisations for cardiovascular diseases are reported in **Table 2**. Except for 12 studies, all others reported a decline in the outcomes assessed during the pandemic period compared to the pre-pandemic period. The declines ranged from 20.2 to 73%. Eleven of the 12 studies reported mostly an increase in stroke hospitalisations during the pandemic period compared to the pre-pandemic period or observed no changes. In the single study by Wadhera and colleagues which evaluated CVD deaths in the USA (15), deaths caused by ischemic heart disease and hypertensive disease increased nationally after the onset of the pandemic in 2020, compared with changes over the same period in 2019, but not for HF, cerebrovascular disease, or other diseases of the circulatory system.

Severity of presentation

The severity of presentation on hospitalisation was reported by 26 studies (**Table 2**). Most studies (n=15) reported that presentation was severe during the pandemic period compared to the pre-pandemic period. A variety of presentations were reported which included higher cardiac enzymes and worse left ventricular ejection fraction for ACS patients, higher admission National Institutes of Health Stroke Scale (NIHSS) scores for stroke patients, higher rates of New York Heart Association (NYHA) III or IV symptoms and severe peripheral oedema for HF patients and higher prevalence of risk factors associated with poorer prognosis in stroke or HF patients. Eleven studies reported no differences in severity of presentation comparing the two periods.

Management on hospitalisation

Thirty-six studies reported data on procedures performed during hospitalisation (**Table 3**). The majority of studies (n=20) reported that less cardiovascular procedures were performed during the pandemic compared to the pre-pandemic periods. Procedures reported included coronary angiographies, PCI and thrombolysis for ACS patients and magnetic resonance imaging, acute revascularization treatments, thrombolysis and thrombectomies for stroke. Fifteen studies reported no differences in these procedures between the periods compared. Only one study reported that stroke patients admitted during the pandemic period were more likely to undergo intravenous thrombolysis and mechanical thrombectomy.

Patient- and system-related delays

Fifty-five studies reported on patient- and health system-related delays during presentation and management (**Table 3**). The majority of studies (n=37) reported more patient- and health system-related delays during the pandemic compared to pre-pandemic times. The most common patient-delay was a longer delay between symptom onset and first medical contact. The longest delay was a median of 10 hours for symptom onset to first medical contact for an acute coronary syndrome during the pandemic compared to a median of about 2 hours pre-pandemic (600 min [298–632] versus 121 min [55–291], $p < 0.001$) (16).

Other measures of delay that were reported included: delays in emergency transport, longer time from symptom onset to consultation and intervention (coronary angiography, PCI, reperfusion or thrombectomy), larger proportion of patients presenting outside of the revascularization window, increase in ischemic time, longer symptom-to-door time, longer medical contact to needle, longer door-to-balloon time, and longer door-to-needle time. Fifteen studies reported no significant differences in patient- and system-related delays. Only three studies reported shorter times between symptom onset and consultation or PCI procedure during the pandemic compared to the pre-pandemic periods.

Reasons for delays in seeking medical care

Only three studies were identified to have assessed the reasons patients provided for their delay in seeking medical care (**Table 3**). The main reasons provided was because of the fear of contracting COVID-19 in hospital as well as adding extra burden to the healthcare system.

Length of stay

Twenty-four studies reported data on length of hospital stay (**Table 3**). Of this number, 10 studies reported a shorter length of stay during the pandemic period (1-8 days) compared with the pre-pandemic period (2-12 days); 10 reported no difference in length of stay between the two periods; and 4 reported a longer length of stay during the pandemic period.

Outcomes related to management

Fifty-four studies reported outcomes related to management (**Table 3**). The majority of studies (n=31) reported no change in in-hospital mortality or discharge disposition among hospitalised patients comparing the pandemic period with pre-pandemic times. Twenty-three studies reported an increase in worse in-hospital outcomes (major adverse cardiac events (MACE), stroke, cardiac and mechanical complications and the need for revascularisation) and in-hospital death during the pandemic compared to the pre-pandemic period.

Discussion

Key findings

Using systematic review methodology, we have assessed the indirect impact of COVID-19 on hospitalisations for cardiometabolic conditions and their management. Based on 103 studies conducted in more than 34 countries across six continents, our results demonstrated the following: (i) the majority of studies had evaluated trends in hospitalisations for ACS followed by acute strokes and HF, with only two studies on hypertension and diabetes; (ii) majority of studies reported declines in hospitalisations during the pandemic compared to pre-pandemic times, with the reductions ranging from 20.2 to 73% and the results were not suggestive of age-specific and gender-related declines; (iii) severe presentation, less utilization of cardiovascular procedures such as coronary angiographies and PCI, and longer patient- and healthcare-related delays were common during the pandemic; (iv) the fear of contracting COVID-19 was the main reason patients provided for the delay in seeking medical care; (v) most studies reported shorter length of hospital stay during the pandemic or no

difference in length of stay; and (vi) finally, the majority of studies reported no change in in-hospital mortality among hospitalised patients comparing the pandemic period with pre-pandemic times.

We identified only one relevant systematic review which assessed the extent to which health services related to the care and management of acute cardiovascular events had been impacted during the COVID-19 pandemic. Kiss and colleagues in a review of 27 studies reported a decrease in stroke and ACS admissions (declines ranging from 12 to 50%) during the COVID-19 period compared to non-COVID-19 periods, a decrease in number of reperfusion procedures, a shortening in the lengths of hospital stay, and longer symptom-to-door times.(17) While the authors only evaluated acute cardiovascular conditions, we adopted a broader approach and focused on all cardiometabolic conditions and evaluated other outcome measures such as severity of presentation, utilization of cardiovascular procedures, both patient and system-related delays, reasons provided by patients for delays in seeking care, and outcomes related to management such as complications, in-hospital mortality and discharge disposition. We have also identified some gaps in the evidence. None of the studies provided specific guidance on how the adverse impact of the pandemic on patients' health-seeking behaviour and response of health systems could be mitigated.

As expected, infectious disease outbreaks have the potential to cause volume changes in emergency department attendances and hospitalisations. These changes have been witnessed in previous epidemics and pandemics such as the 2003 severe acute respiratory syndrome (SARS) outbreak,(18) the 2009 novel influenza A (H1N1) pandemic(19, 20) and the 2015 Middle East respiratory syndrome (MERS) outbreak (21). The unprecedented surge in COVID-19 infection rates and associated substantial morbidity and mortality rates across the globe led policy makers to institute several containment measures ranging from social distancing to lockdowns, to mitigate the disease. Obviously, these measures came at a cost as they impacted on patients' health-seeking behaviors' and the delivery of health services. Several reasons could explain the decline in hospitalisations for cardiometabolic conditions, especially the acute ones. The major reason being the reluctance of patients and their families to initiate medical contact to avoid exposure to COVID-19, as evaluated and reported by three of the included studies in the present review. Other potential reasons include patients not wanting to burden the health system; lack of family support; insufficient ambulance support due to the pressure on the health system and lack of adequate personnel; and restructuring of the healthcare system in response to the pandemic which involved increased hospital capacity for patients infected with COVID-19 and deferral or cancellation of nonessential procedures, routine patient visits and diagnostic evaluations. It is possible the stay-at-home campaigns by governments and the constant information provided by the media were alarming enough for patients to delay seeking medical care (22, 23). Three studies conducted in France, United Arab Emirates (UAE) and Ghana observed an increase in stroke hospitalisations during the pandemic, which could be attributed to an increasing burden of stroke and the fact that the COVID-19 pandemic was not severe especially in Ghana and the UAE. Increased severity at presentation during the pandemic period compared to the pre-pandemic period is likely related to the delays in seeking medical care, effects of the social restrictions such as loneliness, stress, depression, mental health issues and physical inactivity (24-26). Less utilization of cardiovascular procedures, healthcare system delays for procedures and shorter lengths of hospital stay during the pandemic period are likely due to the pressure on healthcare systems, shortage of health personnel because of sickness due to COVID-19 and early discharges to avoid too much exposure in the hospital environment.

These findings have several implications for both patient care and healthcare systems all over the world, given that cardiovascular conditions account for substantial morbidity and over 17 million deaths each year, being the leading cause of mortality in the world.(27). As we come out of the pandemic, preparations for delivering services for cardiovascular diseases needs to take these findings into consideration. The findings should also inform preparations for future pandemics. The declines in hospitalisations for acute cardiovascular conditions are irrespective of age and sex and largely due to fear of contracting COVID-19. This has also been fueled by media and anecdotal reports about patients contracting COVID-19 in the hospital. While there is some truth to this, patients need to be educated on the need to seek medical help promptly and adopt healthy lifestyles in the areas of nutrition and physical activity. Furthermore, given that the decrease in hospitalisations and delays in management could also be due to the adaptations of healthcare systems in response to the pandemic, further restructuring needs to be done to maintain high standards of care and also prepare for future pandemics of this nature.

Strengths and limitations

There are several strengths and limitations of this study that deserve consideration. Compared to the only relevant previous review on the topic(16), our review was more comprehensive and focussed on cardiometabolic conditions and a wide range of measures related to the management of patients. Our literature search was detailed and spanned multiple databases, yielding over 100 articles conducted across 6 continents. The findings may be generalisable globally given that the findings were based on data across 6 out of 7 continents. Though there were a number of limitations, these were all inherent to the included studies and not the actual review. The outcome measures were heterogenous and not consistently reported, hence we were unable to conduct any meta-analysis as originally planned in our published protocol (CRD42021236102). However, we were able to summarise the evidence according to identified consistent themes using narrative synthesis and tables. The findings reported by included studies were based on a diversity of observational study designs which were generally not of high methodological quality. The pandemic and pre-pandemic periods utilised were not consistent across studies, hence it is challenging to make any head-to-head comparisons. Only three out of the 103 studies formally assessed the reasons patients provided for their delay in seeking medical care. Given these limitations, the findings should be interpreted with caution.

Conclusion

Data based on available real-world evidence clearly indicates that health-seeking behaviour of patients for cardiometabolic conditions (particularly the acute ones), their management and outcomes have been adversely impacted by the COVID-19 pandemic. Though the pandemic seemed to have adversely impacted on the management of patients, in-hospital mortality rates were not significantly affected as reported by the majority of studies. None of the studies provided specific guidance on how the adverse impact of the pandemic on patients' health-seeking behaviour and response of health systems could be mitigated. Patients should be educated via population-wide approaches on the need for timely medical contact and health systems should put adequate response strategies in place to provide timely care to patients at high risk and also manage future outbreaks of infectious disease.

Declarations

Declarations of Interests

Dr. Khunti reports personal fees from Amgen , personal fees from Astrazeneca, personal fees from Bayer, personal fees from NAPP, personal fees from Lilly , personal fees from Merck Sharp & Dohme , personal fees from Novartis, personal fees from Novo Nordisk , personal fees from Roche, personal fees from Berlin-Chemie AG / Menarini Group, personal fees from Sanofi-Aventis , personal fees from Servier, personal fees from Boehringer Ingelheim, grants from Pfizer , grants from Boehringer Ingelheim, grants from AstraZeneca, grants from Novartis, grants from Novo Nordisk, grants from Sanofi-Aventis, grants from Lilly, grants from Merck Sharp & Dohme, grants from Servier, outside the submitted work; .

Dr. Seidu reports personal fees from Amgen, personal fees from Astrazeneca, personal fees from NAPP, personal fees from Lilly, personal fees from Merck Sharp & Dohme, personal fees from Novartis, personal fees from Novo Nordisk, personal fees from Roche, personal fees from Sanofi-Aventis, personal fees from Boehringer Ingelheim, grants from AstraZeneca, grants from Sanofi-Aventis, grants from Servier, grants from Janssen, outside the submitted work.

Setor K. Kunutsor and Xavier Cos have no relevant conflicts of interest.

Authors contribution:

Samuel Seidu M.D: literature search, data collection, study design, data interpretation, writing

Setor K. Kunutsor.PhD: Literature search, data collection, analysis, data interpretation, writing.

Xavier Cos. PhD: data interpretation, writing, editing

Kamlesh Khunti PhD: study design, literature search, data interpretation, writing

Funding:

This study was supported with a research grant from Primary Care Diabetes Europe (PCDE). PCDE as a society, has received sponsorship from Novo Nordisk, Eli Lilly and Roche Diagnostics, but the companies had no input in the study

Data sharing

The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This study is based in data from published articles.

References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The lancet*. 2020;395(10229):1054–62.
2. Wu Z, McGoogan J. Characteristics of and Important Lessons From the 367 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 368 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;369.
3. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. *Ann Med*. 2020;52(7):345–53.
4. Kunutsor SK, Laukkanen JA. Cardiovascular complications in COVID-19: A systematic review and meta-analysis. *J Infect*. 2020 Aug;81(2):e139-41.
5. Kunutsor SK, Laukkanen JA. Hepatic manifestations and complications of COVID-19: A systematic review and meta-analysis. *J Infect*. 2020 Sep;81(3):e72-4.
6. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. *N Engl J Med*. 2020.
7. Kunutsor SK, Laukkanen JA. Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis. *J Infect*. 2021 Jan;82(1):159–98.
8. Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann-Boyce J, Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. *Endocrinology diabetes metabolism*. 2021;4(1):e00176.
9. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet*. 2020 Mar;28(10229):1014–5. 395(.
10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA*. 2000;283(15):2008–12.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
12. Wells GA, Shea B, O'Connell Da, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
13. Kunutsor SK, Apekey TA, Laukkanen JA. Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence. *Eur J Epidemiol*. 2015;30(8):599–614.

14. Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. *Eur Heart J*. 2020;41(19):1852–3.
15. Wadhera RK, Shen C, Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular deaths during the COVID-19 pandemic in the United States. *J Am Coll Cardiol*. 2021;77(2):159–69.
16. Hauguel-Moreau M, Pillière R, Prati G, Beaune S, Loeb T, Lannou S, et al. Impact of Coronavirus Disease 2019 outbreak on acute coronary syndrome admissions: four weeks to reverse the trend. *J Thromb Thrombolysis*. 2021;51(1):31–2.
17. Kiss P, Carcel C, Hockham C, Peters SA. The impact of the COVID-19 pandemic on the care and management of patients with acute cardiovascular disease: a systematic review. *European Heart Journal-Quality of Care Clinical Outcomes*. 2021;7(1):18–27.
18. Huang C, Yen DH, Huang H, Kao W, Wang L, Huang C, et al. Impact of severe acute respiratory syndrome (SARS) outbreaks on the use of emergency department medical resources. *Journal of the Chinese Medical Association*. 2005;68(6):254–9.
19. Fagbuyi DB, Brown KM, Mathison DJ, Kingsnorth J, Morrison S, Saidinejad M, et al. A rapid medical screening process improves emergency department patient flow during surge associated with novel H1N1 influenza virus. *Ann Emerg Med*. 2011;57(1):52–9.
20. Miroballi Y, Baird JS, Zackai S, Cannon J, Messina M, Ravindranath T, et al. Novel influenza A (H1N1) in a pediatric health care facility in New York City during the first wave of the 2009 pandemic. *Arch Pediatr Adolesc Med*. 2010;164(1):24–30.
21. Lee SY, Khang YH, Lim HK. Impact of the 2015 Middle East Respiratory Syndrome Outbreak on Emergency Care Utilization and Mortality in South Korea. *Yonsei Med J*. 2019 Aug;60(8):796–803.
22. Moroni F, Gramegna M, Ajello S, Beneduce A, Baldetti L, Vilca LM, et al. Collateral damage: medical care avoidance behavior among patients with myocardial infarction during the COVID-19 pandemic. *Case Reports*. 2020;2(10):1620–4.
23. Wessler BS, Kent DM, Konstam MA. Fear of coronavirus disease 2019—an emerging cardiac risk. *JAMA cardiology*. 2020;5(9):981–2.
24. Holt-Lunstad J, Smith TB, Baker M, Harris T, Stephenson D. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. *Perspectives on psychological science*. 2015;10(2):227–37.
25. Lima CKT, de M Carvalho, Moreira P, Lima, Igor de Araújo Araruna Silva, de Oliveira Nunes, José Victor Alexandre, Saraiva JS, de Souza RI, et al. The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease). *Psychiatry Res*. 2020;287:112915.
26. Redfors P, Isaksén D, Lappas G, Blomstrand C, Rosengren A, Jood K, et al. Living alone predicts mortality in patients with ischemic stroke before 70 years of age: a long-term prospective follow-up study. *BMC Neurol*. 2016;16(1):1–8.
27. Mann DL, Zipes D, Libby P, Bonow R. Braunwald's heart disease: a textbook of cardiovascular medicine 9th ed.. 2012.

Tables

Table 1. Baseline characteristics of included studies

Author, year of publication	Period of data collection	Pandemic period / lockdown	Pre-pandemic period / pre-lockdown	Historical control period / pre-COVID-19	Study design	Country	Location	Source of data	Male %
Araiza-Garaygordobil, 2021		12 Mar to 15 Apr, 2020	1 Dec 2019 to 11 Mar 2020	Dec 2018 to April 2019	Ecological retrospective study	17 countries	Intercontinental		
Mafham, 2020	1 Jan 2019 to 24 May, 2020	March to May 2020	Jan 2019 to Feb 2020		Retrospective cohort	England	Europe	Acute NHS hospital trusts	
Perrin, 2020		13 Mar to 30 Apr 2020		13 Mar to 30 Apr 2019 and pre-pandemic period (7 Jan to 24 Feb 2020)	Retrospective cohort	Switzerland	Europe	Geneva University Hospitals	Pandemic (80); Control (75)
Tam, 2020	1 Nov 2019 to 31 Mar 2020	After 25 Jan 2020	Before 25 Jan 2020		Cross-sectional study	Hong Kong	Asia	Accident and Emergency Department	Pandemic (70.3); Control (65.9)
Toniolo, 2020		Mar-20		Mar-19	Retrospective cohort	Italy	Europe	Cardiology Division of Udine University Hospital	
Huet, 2020		17-22 Mar 2020	2-6 Mar 2020		Cross-sectional study	France	Europe	Intensive cardiac units of 9 cardiology centres	
Kwok, 2020b	Jan 2017 to April 2020	After 23 March 2020	Before 23 March 2020		Retrospective cohort	UK	Europe	British Cardiovascular Intervention Society-National Institute of Cardiovascular Outcomes Research database	
Boukhris, 2020		1 Jan to 30 April 2020		1 Jan to 30 April 2019	Cross-sectional study	Russia, Brazil, Saudi Arabia, Tunisia	Intercontinental		
Braiteh, 2020		March to April 2020		March to April 2019	Retrospective cohort	USA	North America	Upstate New York Hospitals	Pandemic (70.1); Control (61.9)
Butt, 2020		January and March 2020		Mar-19	Retrospective cohort	Qatar	Asia	Hamad Medical Corporation	
De Filippo, 2020		20 Feb to 31 March 2020	1 Jan to 19 Feb 2020	20 Feb to 31 March 2019	Retrospective cohort	Italy	Europe	15 Hospitals	Pandemic (76.8)
De Rosa, 2020		12-19 March 2020		12-19 March 2019	Cross-sectional study	Italy	Europe	Cardiac care units	
Fileti, 2020		10 March to 10 April 2020		10 March to 10 April 2019	Retrospective cohort	Italy	Europe	2 Hospitals with cardiac catheterization facilities	Pandemic (65.3); Control (64.9)
Folino, 2020		2020		2019	Cross-sectional study	Italy	Europe	10 Cardiological centres in Northern Italy	

Author, year of publication	Period of data collection	Pandemic period / lockdown	Pre-pandemic period / pre-lockdown	Historical control period / pre-COVID-19	Study design	Country	Location	Source of data	Male %
Haddad, 2020		mid-March to mid-May 2020	Jan to mid-March 2020	mid-March to mid-May 2019	Retrospective cohort	Canada	North America	Hospitals in the Greater Montreal area	Pandemic (44); Pre-pandemic (42); Control (42)
Hauguel-Moreau, 2020	Weeks 8-7, 2018-2020	17 Feb to 26 April 2020		17 Feb to 26 April 2018; 17 Feb to 26 April 2019	Retrospective cohort	France	Europe	High volume PCI coronary unit	
Holy, 2020		Before and after 16 March 2020 (lockdown)		Before and after 16 March 2019	Cross-sectional study	Switzerland	Europe	University Heart Center Zurich	
Metzler, 2020		2-29 March 2020			Cross-sectional study	Austria	Europe	PCI centres	
Montagnon, 2021		23 March to 5 April 2020		23 March to 5 April 2019	Cross-sectional study	France	Europe	Hospital Sainte Anne	ACS - Pandemic (71.4); Control / Stroke plus T Pandemic (70); Control (55.6)
Showkathali, 2020		25 March to 31 May 2020		25 March to 31 May 2018; 25 March to 31 May 2019	Retrospective cohort	India	Asia	Tertiary referral hospital	
Sokolski, 2020		1 March to 30 April 2020		1 March to 30 April 2019	Retrospective cohort	12 countries	Europe	15 centres in Europe	
Solomon, 2020		Before and after 4 March 2020		Before and after 4 March 2019	Retrospective cohort	USA	North America	Kaiser Permanente Northern California	
Vacanti, 2020		1 Jan to 30 June 2020		2 Jan to 30 June 2018; 1 Jan to 30 June 2019	Retrospective cohort	Germany	Europe	Cardiology Dept	
Yalamanchi, 2020		22 March to 1 August 2020		22 March to 1 August 2018; 22 March to 1 August 2019	Retrospective cohort	India	Asia	Cardiac intensive care unit	
Tsioufis, 2020		1 Jan to 30 April 2020		1 Jan to 30 April 2018; 1 Jan to 30 April 2019	Retrospective cohort	Greece	Europe	Cardiology Dept of a Tertiary General Hospital	
Gasior, 2020		9 March to 16 April 2020		9 March to 16 April 2019	Retrospective cohort	Poland	Europe	Polish National Health Fund	
Dreger, 2020		Weeks 2-21 2020		Weeks 2-21 2017 to 2019	Retrospective cohort	Germany	Europe	Hospitals in Berlin	
Anderson, 2020		11 March to 28 April 2020		11 March to 28 April 2019	Retrospective cohort	USA	North America	Hospital in Boston	
Gluckman, 2020	30 Dec 2018 to 16 May 2020	29 March 2020 to 16 May 2020	23 Feb 2020 to 28 March 2020	30 Dec 2018 to 22 Feb 2020	Cross-sectional study	USA	North America	49 hospitals in the Providence St Joseph Health system	Later COVID period Early (19 per (68); Historical control

Author, year of publication	Period of data collection	Pandemic period / lockdown	Pre-pandemic period / pre-lockdown	Historical control period / pre-COVID-19	Study design	Country	Location	Source of data	Male %
Mohammad, 2020		1 March to 7 May 2020		1 March to 7 May 2015-2019	Retrospective cohort	Sweden	Europe	Swedish Coronary Angiography and Angioplasty Registry	Pandemic (67.4) Control (67.4)
Piccolo, 2020	30 Jan to 26 March 2020	4 weeks after 27 Feb 2020	4 weeks before 27 Feb 2020		Retrospective cohort	Italy	Europe	PCI centres	Pandemic (75%) Control (72%)
Secco, 2020		Mar-20		Mar-19	Retrospective cohort	Italy	Europe	3 High volume hospitals	Pandemic (67.4) Control (67.4)
Ayad, 2021		1 Feb to October 2020		1 Feb to October 2019	Retrospective cohort	Egypt	Africa	International Cardiac Center hospital	Pandemic (81.5) Control (85.7)
Bhatt, 2020	1 Jan 2019 to 31 March 2020	Mar-20		Mar-19	Retrospective cohort	USA	North America	Mass General Brigham health system	Pandemic (55.4) Control (57.8)
Daoulah, 2021		1 January to 30 April 2020		1 January to 30 April 2018-2019	Retrospective cohort	Saudi Arabia	Asia	16 centres	2018-2019-2020
Desai, 2020		Mar-20		March 2017-2019	Retrospective cohort	USA	North America	Stroke center	
Diegoli, 2020		After 17 March 2020		2019	Retrospective cohort	Brazil	South America	Joinville Stroke Registry	
Gitt, 2020		1 March to 21 April 2020		1 March to 21 April 2017-2019	Retrospective cohort	Germany	Europe	Heart Center Ludwigshafen	
Hammad, 2020	1 Jan to 15 April 2020	After 23 March 2020	Before 23 March 2020		Retrospective cohort	USA	North America	Integrated 18-hospital system	Pandemic (49); Pre-pandemic (67)
Kerleroux, 2020		15 Feb to 30 March 2020		15 Feb to 30 March 2019	Prospective cohort	France	Europe	32 stroke centres	Pandemic (51.2) Control (58.4)
Montaner, 2020		Before and after 31 March 2020		Before and after 31 March 2019	Prospective cohort	Spain	Europe	Stroke units	
Neves Briard, 2020		30 March to 31 May 2020		30 March to 31 May 2019	Prospective cohort	Canada	North America	Stroke center	Pandemic (48); Control (51)
Pop, 2020		1-31 March 2020		1-31 March 2019	Retrospective cohort	France	Europe	3 Stroke units	
Popovic, 2020		26 Feb to 10 May 2020		2008-2017	Prospective cohort	France	Europe	University Hospital of Nancy	Pandemic (56.3) Control (76.1)
Range, 2020	15 Jan 2019 to 14 April 2020	15 March to 14 April 2020		Before 15 March 2020	Prospective cohort	France	Europe	France PCI registry	Pandemic (70.5) Control (76.1)
Reinstadler, 2020		24 Feb (week 9) to 5 April 2020 (week 14)			Retrospective cohort	Austria	Europe	7 tertiary care hospitals	73

Author, year of publication	Period of data collection	Pandemic period / lockdown	Pre-pandemic period / pre-lockdown	Historical control period / pre-COVID-19	Study design	Country	Location	Source of data	Male %
Sarfo, 2020		January to June 2020		January to June 2019	Retrospective cohort	Ghana	Africa	Komfo Anokye Hospital	Pandemic (57.1); Control (53.4)
Teo, 2020		23 Jan to 24 March 2020		23 Jan to 24 March 2019	Retrospective cohort	Hong Kong	Asia	Queen Mary Hospital	Pandemic (43.8); Control (50.6)
Toner, 2020		16 March to 15 April 2020		16 March to 15 April 2014-2019	Prospective cohort	Australia	Oceania	Tertiary hospital	Pandemic (65.0); Control (71.6)
Abdelaziz, 2020		1-31 March 2020		1-31 March 2019	Retrospective cohort	UK	Europe	Tertiary cardiac center	Pandemic (69.6); Control (76.8)
Agarwal, 2020	01 June 2019 to 15 May 2020	1 March 2020 to 15 May 2020	1 June 2019 to 29 Feb 2020		Retrospective cohort	USA	North America	Langone Health Stroke Center	Pandemic (49.2); pandemic (54.7)
Burgos, 2020		Feb to March 2020		Feb to March 2019	Retrospective cohort	Argentina	South America	Cardiology center	
Aldujeli, 2020		11 March to 20 April 2020		11 March to 20 April 2019	Retrospective cohort	Lithuania	Europe	Lithuanian University of Health Sciences Kaunas Clinics	NSTEMI Pandemic (73); Control (60) / STEMI Pandemic (72); Control (65)
Andersson, 2020		1 Jan to 11 March 2020 / 12 -31 Mar 2020		1 Jan to 11 March 2019 / 12 -31 Mar 2019	Retrospective cohort	Denmark	Europe	Danish Nationwide Patient Registry	Pandemic New-onset HF (61); Control New-onset HF (61); Control New-onset HF (61)
Ball, 2020		28 Oct 2019 to 10 May 2020		28 Oct 2019 to 10 May 2018-2019	Cross-sectional study	UK	Europe	9 Hospitals	
Boeddinghaus, 2020		March to April 2020	Jan to Feb 2020	March to April 2019	Retrospective cohort	Switzerland	Europe	Tertiary University Hospital	Pandemic (77.5); pandemic (76.8)
Bromage, 2020		2 March to 19 April 2020		2 March to 19 April 2017-2019	Retrospective cohort	UK	Europe	King's College Hospital	Pandemic (54); Control (58)
Bryndza, 2021		March to April 2020		March to April 2020	Retrospective cohort	Poland	Europe	Cardiology center	
Cammalleri, 2020		1-31 March 2020		Mar-19	Retrospective cohort	Italy	Europe	Cardiology Department	Pandemic (85); Control (87)
Candelaresi, 2021		9 March to 12 April 2020	2 Feb to 8 March 2020	Same period in 2019	Retrospective cohort	Italy	Europe	5 Campania stroke hubs	
Chew, 2021		7 Feb to 31 March 2020	1 October 2019 to 6 Feb 2020		Retrospective cohort	Singapore	Asia	National University Hospital Singapore	Pandemic (56.8); pandemic (64.4)

Author, year of publication	Period of data collection	Pandemic period / lockdown	Pre-pandemic period / pre-lockdown	Historical control period / pre-COVID-19	Study design	Country	Location	Source of data	Male %
Choudhary, 2020		25 March to 24 April 2020	25 Feb to 24 March 2020	25 Jan to 24 Feb 2020	Retrospective cohort	India	Asia	4 Tertiary regional Eds	
Çinier, 2020		5 March to 6 April 2020		5 March to 6 April 2020	Retrospective cohort	Turkey	Europe	Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital	Pandemic (81.1) Control (85.6)
Colivicchi, 2020		20 Feb to 20 April 2020		20 Feb to 20 April 2019	Retrospective cohort	Italy	Europe	San Filippo Neri Hospital	Pandemic (79); Control (57)
Cummings, 2020		March to April 2020		March 2019 to Feb 2020	Retrospective cohort	USA	North America	Telestroke registry at Medical University of South Carolina	Pandemic (44); Control (46.9)
Del Pinto, 2020		1 January to 31 March 2020		1 January to 31 March 2019	Retrospective cohort	Italy	Europe	5 Hospitals in L'Aquila	
Enache, 2020		First 3 months of 2020		First 3 months of 2019	Retrospective cohort	Monaco	Europe	Cardiology Departments	
Erol, 2020		17 April to 2 May 2020		1-15 November 2018	Prospective cohort	Turkey	Europe	Registries	Pandemic (76.2) Control (73.7)
Frisullo, 2020		11 March to 11 April 2020		11 March to 11 April 2019	Retrospective cohort	Italy	Europe	ED of Policlinico A. Gemelli Hospital	Pandemic (59.6) Control (46.3)
Giannouchos, 2021		1 Jan to 31 Aug 2020		1 Jan to 31 Aug 2019	Cross-sectional study	USA	North America	University of Utah Healthcare Systems	
Hoyer, 2020		Weeks 1-15 2020		Weeks 1-15 2019	Retrospective cohort	Germany	Europe	4 stroke centers	
Hsiao, 2020		Weeks 11-15 2020	Weeks 1-10 2020	mid-March to mid-April 2019	Retrospective cohort	USA	North America	30 Healthcare facilities	
JF Huang, 2020		11 March to 9 April 2020	10 Feb to 10 March 2020		Cross-sectional study	USA	North America	Mayo Clinic telestroke network	
Ikenberg, 2020	1 Jan to 19 April 2020	21 March to 19 April 2020	1 Jan to 20 March 2020		Retrospective cohort	Germany	Europe	Bavarian Comprehensive Stroke Center	
Jasne, 2020		1 Jan to 28 April 2020		1 Jan to 28 April 2019	Cross-sectional study	USA	North America	3 Connecticut hospitals	49.7
John, 2020		1 March to 10 May 2020		1 March to 10 May 2019	Retrospective cohort	UAE	Asia	Cleveland Clinic Abu Dhabi	Pandemic Ischemic stroke (72.3) hemo stroke (66.7) Control Ischemic stroke (67.9) hemo stroke

Author, year of publication	Period of data collection	Pandemic period / lockdown	Pre-pandemic period / pre-lockdown	Historical control period / pre-COVID-19	Study design	Country	Location	Source of data	Male %
Kobo, 2020		20 March to 30 April 2020		20 March to 30 April 2019	Prospective cohort	Israel	Asia	4 Cardiac centers	Pandemic (84.1); Control (81.5)
Kuitunen, 2020	1 February to 30 April 2020	6 weeks after 16 March 2020	6 weeks before 16 March 2020	Corresponding period in 2019	Retrospective cohort	Finland	Europe	3 Emergency Departments	
Lauridsen, 2020		12 March to 13 May 2020		12 March to 13 May 2015-2019	Retrospective cohort	Denmark	Europe	Danish Civil Population Registry	Pandemic (71); Control (75)
Little, 2020		1 March to 30 April 2020		1 March to 30 April 2019	Retrospective cohort	UK	Europe	7 Heart Attack Centres	Pandemic (80); Control (78)
Nagamine, 2020		March to April 2020		March to April 2019	Retrospective cohort	USA	North America	Stroke center	Pandemic (75); Control (61)
Mitra, 2020		26 March to 23 April 2020		26 March to 23 April 2019	Cross-sectional study	Australia	Oceania	Tertiary cardiology and neurosciences centre	Pandemic (67.3); Control (84.2)
Nguyen-Huynh, 2020		15 March to 9 May 2020	1 Jan 2019 to 14 March 2020		Retrospective cohort	USA	North America	Kaiser Permanente Northern California	Pandemic (47.9); Control (47.1)
Oseran, 2020		1 March to 30 April 2020	1 Jan to 29 Feb 2020	1 March to 30 April 2019 / 1 Jan to 28 Feb 2019	Cross-sectional study	USA	North America	8 Acute care hospitals	
Paliwal, 2020	November 2019 to April 2020	7 Feb to 30 April 2020	1 Nov 2019 to 7 Feb 2020		Retrospective cohort	Singapore	Asia	Stroke center	Pandemic (57); Pre-pandemic (20)
Papafakis, 2020		2 March to 12 April 2020		2 March to 12 April 2019	Retrospective cohort	Greece	Europe	Public hospitals	Pandemic (79.1); Control (76.2)
Piuhola, 2020		Mar-20	Jan to Feb 2020	January to Feb 2017-2019	Retrospective cohort	Finland	Europe	5 Tertiary centers	
Rashid Hons, 2020		1 Feb to 14 May 2020		1 Feb to 14 May 2019	Retrospective cohort	UK	Europe	Myocardial Ischaemia National Audit Project/British Cardiovascular Intervention Society	Pandemic (71.2); Control (79.5)
Richter, 2021		16 March to 15 May 2020	16 Jan to 15 March 2020	16 March to 15 May 2019	Retrospective cohort	Germany	Europe	1463 Hospitals	
Rodríguez-Leor, 2020		16 March to 14 April 2020		1-30 April 2019	Retrospective cohort	Spain	Europe	75 STEMI care centers	Pandemic (78.4); Control (78.4)
Ruparelia, 2020		After 20 March 2020	Jan to Feb 2020	Jan to March 2019	Retrospective cohort	UK	Europe	2 Large Hospitals	Pandemic (65.3); Control (68.9)
Schirmer, 2020		Feb to March 2020		Feb to March 2019	Retrospective cohort	USA	North America	12 Stroke centers	
Seiffert, 2020	1 Jan 2019 to 31 May 2020	Jan to May 2020		Jan to May 2019	Retrospective cohort	Germany	Europe	Insurance Claims Data	

Author, year of publication	Period of data collection	Pandemic period / lockdown	Pre-pandemic period / pre-lockdown	Historical control period / pre-COVID-19	Study design	Country	Location	Source of data	Male %
Sharma, 2020		30 Dec 2019 to 19 April 2020		31 Dec 2018 to 21 April 2019	Retrospective cohort	USA	North America	5 Tertiary stroke centers	
Siegler, 2020		1 March 2020 to 15 April 2020	1 October 2019 to 29 Feb 2020		Retrospective cohort	USA	North America	Stroke center	Pandemic (57); Control (59)
Tejada Meza, 2020	30 Dec 2019 to 3 May 2020	After 14 March 2020	Before 14 March 2020		Retrospective cohort	Spain	Europe	Tertiary hospitals of the NORDICTUS network	
Uchino, 2020		9 March to 2 April 2020	1 Jan to 8 March 2020		Retrospective cohort	USA	North America	19 Emergency departments	
Vensentini, 2020		March to April 2020	March to April 2010-2019		Prospective cohort	Argentina	South America	6 Cardiovascular Intensive Care Units	
Wadhera, 2021		18 March to June 2020	1 Jan to 17 March 2020	Jan to June 2019	Retrospective cohort	USA	North America	National Center for Health Statistics	
J Wang, 2020		12 March to 30 June 2020	1 Dec 2019 to 11 Mar 2020		Retrospective cohort	USA	North America	Inova Fairfax Medical Campus	Pandemic (53.3); Control (51.9)
Yang, 2020		23 Jan to 7 March 2020	1 December 2019 to 14 Jan 2020		Retrospective cohort	China	Asia	Stroke center	Pandemic (71.4); Control (64.7)
Zhao, 2020		Feb-20		Feb-19	Retrospective cohort	China	Asia	Big Data Observatory Platform for Stroke of China & 280 stroke centers	
Cox, 2020		22 March to 20 April 2020		22 March to 20 April 2019	Retrospective cohort	USA	North America	Vanderbilt University Medical Center	

Table 2. Trends in hospitalisations of cardiometabolic conditions and severity at presentation

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Araiza-Garaygordobil, 2021	ACS admissions	8750	5923	1444	Compared to the pre-pandemic period, a significant overall trend for reduction of 20.2% in the weekly number of ACS hospitalizations was observed during the pandemic period. There were also reductions when compared to the historical period.	
Mafham, 2020	ACS admissions		Monthly average for 2019 (13,075); Jan 2020 (13,645); Feb 2020 (12,443)	Mar 2020 (10,118); Apr 2020 (8,739); May 2020 (9756)	From mid-February 2020, hospital admissions fell from a 2019 baseline rate of 3017 admissions per week to 1813 per week by the end of March, 2020 (reduction of 40%). This decline was partly reversed during April and May, 2020, such that by the last week of May, 2020, there were 2522 admissions, representing a 16% reduction from baseline.	
Perrin, 2020	Undergoing PCI for ACS	140		45	The incidence rate of ACS was lower during the COVID-19 period than the control period (0.7 vs 1.1 per 1000 person-years, $p < 0.01$). There were significantly more patients presenting with out-of-hospital cardiac arrest during the COVID-19 period compared with the control period (22.2% vs 7.1%, $p < 0.01$).	ACS patients presented higher cardiac enzymes during the COVID-19 period compared with the control period.
Tam, 2020	MI admissions		85	64	There was a reduction in daily emergency room attendance since January 25, 2020 (231 per day compared to 327 per day before the pandemic)	
Toniolo, 2020	Severe emergent CVD admissions	71		34	A decrease was observed in all SECDs hospital admissions comparing the pandemic to the control period: 27 versus 19 for STE-ACS (-30%); 44 versus 15 for non-STE-ACS (-66%) and 46 versus 23 for atrioventricular-block/acute sinus node dysfunction (-50%).	
Huet, 2020	Acute myocardial infarction or acute heart failure admissions				Before containment, the nine participating intensive cardiac care units admitted 4.8 ± 1.6 patients per day, versus 2.6 ± 1.5 after containment.	
Kwok, 2020b	PCI procedures for STEMI		33255	683	A 43% decline in monthly average procedures was recorded between 2017 and 2019 (865) to 497 in April 2020	
Boukhris, 2020	Volume of ACS and ischemic strokes	ACS (2398); ischemic stroke (4027)		ACS (2215); ischemic stroke (3905)	ACS volume tended to increase in January and February 2020 in comparison to the same period in 2019. In March and April 2020, STEMI and NSTEMI decreased in comparison with March and April 2019. There was a gradual decrease in stroke cases from January to March 2020 compared to 2019, followed by an increase in April 2020.	
Braiteh, 2020	ACS admissions	113		67	Drop by 40.7% in total ACS cases during the pandemic in comparison to 2019	
Butt, 2020	ACS, other CVDs, stroke	ACS (171); other CVDs (116); stroke (109)		March 2020 - ACS (114); other CVDs (64); stroke (83)	Compared to March 2019, there was a decrease in ACS, other CVDs, and stroke by 50%, 81.3% and 31.3% respectively, in March 2020	

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
De Filippo, 2020	ACS admissions	ACS (756)	ACS (899)	ACS (547)	13.3 ACS admissions/day during the pandemic period compared to 18.0 for the pre-pandemic period and 18.9 for the historical period. The corresponding values for STEMI were 6.1, 7.8 and 8.0. That for NSTEMI were 4.2, 7.1 and 7.5. Unstable angina was 3.1, 3.1 and 3.4.	
De Rosa, 2020	AMI admissions	AMI (618); STEMI (268); NSTEMI (350)		AMI (319); STEMI (197); NSTEMI (122)	48.4% reduction in AMI admissions during the pandemic period compared to 2019. Reductions were significant for both STEMI and NSTEMI. The reductions for STEMI were higher for women compared to men. Reductions in admissions for HF, AF and PE during the pandemic compared to 2019.	
Fileti, 2020	ACS admissions	ACS (94); STEMI (36); NSTEMI (58)		ACS (72); STEMI (34); NSTEMI (38)	23.4% reduction in ACS admissions during 2020 compared to 2019, with a decrease for both STEMI and NSTEMI	
Folino, 2020	Access to coronary care unit for ACS	NSTEMI in first 8 weeks of 2019 (260) and 221 in the following 5 weeks. Corresponding values for STEMI were 22 and 21			After the eighth week of 2020, there was a significant reduction in access to CCU for NSTEMI compared to the same period of the previous year, but not for STEMI.	
Haddad, 2020	STEMI admissions	60	54	53	Number of STEMI admissions were unaffected during the pandemic period	
Hauguel-Moreau, 2020	ACS admissions				In 2020, there were two distinct phases in ACS admissions - a first significant fall, with a relative reduction of 73%, from the week of lockdown (week 12) to 3 weeks later followed by an increase	
Holy, 2020	ACS and OHCA referrals				Four weeks after March 16th 2020 ACS referrals decreased by 42% (NSTEMI: -49%, STEMI: -56%, unstable angina: +37%) while OHCA referrals declined by 57%	
Metzler, 2020	ACS admissions				Comparing the first and last calendar week of the period surveyed, there was a relative reduction of 39.4% in admissions for ACS. STEMI admissions reduced from 94 to 70 and NSTEMI from 132 to 67	
Montagnon, 2021	Admissions for ACS and strokes	ACS (12); Stroke or TIA (27)		ACS (7); Stroke or TIA (30)	There were five fewer cases of ACS in 2020, a reduction of 41.7% compared with 2019. In 2020, an increase was observed in the number of strokes and TIAs, with 27 cases in 2019 as opposed to 30 in 2020.	
Showkathali, 2020	ACS admissions	183		104	During the study period in 2020, 104 patients were admitted with ACS, which is a 43% decline in admissions compared to the same time period in the previous 2 years (183). The decline in STEMI, NSTEMI and unstable angina admissions were 47%, 33%, and 54% respectively	

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Sokolski, 2020	Cardiovascular admissions	4452		3007	In 2020, there were fewer admissions for ACS, acute HF, arrhythmia, and others. There was a relatively higher percentage of pulmonary embolism admissions in 2020	
Solomon, 2020	AMI admissions				The weekly rates of hospitalization for AMI decreased by up to 48% during the Covid-19 period	
Vacanti, 2020	ACS admissions	2018 (326); 2019 (353)		270	Decline in ACS admissions in 2020 compared to 2019 and 2018, representing a decline of 24% and 19%, respectively.	
Yalamanchi, 2020	ACS admissions	2018 (307); 2019 (322)		216	Decline in ACS admissions in 2020 compared to 2019 and 2018, representing a decline of 33% and 30%, respectively. There was a decline in admissions for acute decompensated heart failure, arrhythmia, and other diagnoses in 2020, which were 38%, 62%, and 59%, respectively; while there was a 50% increase in acute pulmonary embolism admission compared to the mean admission in 2018 and 2019	
Tsioufis, 2020	AMI admissions				The number of AMI cases in March 2020 was the lowest compared to the entire three year period. Similar significant findings were observed for STEMI and NSTEMI. Cases of HF and CAD were also lower in 2020 compared to the preceeding periods	
Gasior, 2020	AMI admissions				The number of admissions for AMI dropped on average by 43.6%	
Dreger, 2020	AMI admissions	2017 (255); 2018 (250); 2019 (257)		207	There was a reduction in AMI admissions in 2020 compared with the same time period in the three previous years.	
Anderson, 2020	Admissions for cardiometabolic conditions				Overall decrease in cardiometabolic conditions (CVD, strokes, VTE, HF and diabetes)	
Gluckman, 2020	AMI admissions	13329	Early COVID-19 period (860)	Later COVID-19 period (1055)	Beginning February 23, 2020, AMI-associated hospitalizations decreased for 5 weeks (early COVID-19 period). Thereafter, AMI-associated hospitalizations increased during the later COVID-19 period	
Mohammad, 2020	MI cases referred for coronary angiography	15213		2443	The incidence of MI referred for invasive treatment was reduced during the COVID-19 pandemic	
Piccolo, 2020	PCI procedures for ACS		178 cases/100000 residents per year	120/100000 residents per year	During the 8 week period, there was a decline by 32% in the number of PCIs for ACS. In the last 2 weeks of the observational period, PCIs for ACS were reduced by 50%. The reduction was similar for STEMI and NSTEMI	
Secco, 2020	ACS admissions	162		84	Hospitalization for ACS decreased from 162 patients in 2019 to 84 patients in 2020	
Ayad, 2021	STEMI patients requiring PCI	364		270	During the COVID-19 period, the number of PCI procedures was reduced by 25.7% compared with previous year	
Bhatt, 2020	Acute cardiovascular conditions	404		231	There were 43.4% fewer estimated daily hospitalizations in March 2020 compared with March 2019	

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Daoulah, 2021	STEMI admissions	2018 (650); 2019 (635)		500	STEMI volumes were reduced by 28% during the pandemic period	
Desai, 2020	Stroke and TIA admissions	Strokes - 2017 (163); 2018 (161); 2019 (159) / TIA - 2017 (11); 2018 (18); 2019 (16)		Stroke (96); TIA (6)	Number of acute ischemic strokes and TIAs decreased by 40% and 60% respectively, from March 2017-2019 to March 2020	
Diegoli, 2020	Stroke admissions	12.9 cases/100000		8.3 cases/100000	When compared with the same period in 2019, there was a 36.4% reduction in stroke admissions in 2020	No differences in admissions for stroke severity
Gitt, 2020	ACS admissions	STEMI (49); NSTEMI (95); UA (94)		STEMI (46); NSTEMI (50); UA (48)	During the pandemic, there was a 50% reduction in both unstable angina and NSTEMI	
Hammad, 2020	STEMI admissions		108	35	Lower STEMI admissions during the pandemic period.	Post-COVID-19 presentation was severe compared to pre-COVID-19
Kerleroux, 2020	Stroke patients receiving mechanical thrombectomy	844		668	There was a 21% significant decrease in MT case volumes during the pandemic period	
Montaner, 2020	Stroke admissions				25% reduction in stroke admissions during the pandemic period. 40% reductions in TIAs attending the emergency department	
Neves Briard, 2020	Stroke admissions	138		156	The first two months of the COVID-19 pandemic were not associated with a decrease in acute stroke evaluations	
Pop, 2020	Stroke admissions	167		122	Compared to the same period in 2019, there were 39.6% fewer stroke alerts in 2020	
Popovic, 2020	STEMI patients undergoing PCI	1552		83		
Range, 2020	STEMI patients undergoing PCI	1942		122	There was a significant drop (12%) in mean number of STEMI/month in the lockdown group compared with prelockdown (139 vs 122, P < 0.04).	
Reinstadler, 2020	STEMI patients referred for PCI			163	Rates of STEMI admissions decreased (calendar week 9/10 (n = 69, 42%); calendar week 11/12 (n = 51, 31%); calendar week 13/14 (n = 43, 26%))	
Sarfo, 2020	Stroke admissions	401		431	Stroke admissions were higher during the pandemic period (increase of 7.5%). Recurrent stroke admissions were also higher during the pandemic period	
Teo, 2020	Stroke admissions	89		73	Fewer stroke admissions in pandemic period	No differences in stroke severity
Toner, 2020	ACS undergoing PCI	102		20	The case volume for the number of ACS patients undergoing PCI was not significantly different in the COVID and non-COVID eras	
Abdelaziz, 2020	STEMI patients undergoing PCI	69		46	Fewer STEMI admissions in the pandemic period	Higher cardiac troponin-I levels on admission in STEMI patients during pandemic than pre-COVID era

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Agarwal, 2020	Acute ischemic stroke care		634	120	Fewer admissions during pandemic compared to pre-pandemic	Pandemic patients presented with a higher median admission NIHSS scores.
Burgos, 2020	HF admissions	49		36	26.5% decrease in number of HF admissions during the pandemic period	
Aldujeli, 2020	AMI admissions	NSTEMI (62); STEMI (60)		NSTEMI (30); STEMI (47)	Fewer admissions during pandemic compared to pre-pandemic	
Andersson, 2020	New-onset and worsening HF admissions	New-onset HF (2819); Worsening HF (1419)		New-onset HF (2595); Worsening HF (1364)	In the lockdown period, rates of new-onset HF diagnoses and of hospitalizations for worsening HF were significantly lower in 2020 versus 2019	
Ball, 2020	CVDs admissions				Activity for cardiac, cerebrovascular and other vascular conditions started to decline 1–2 weeks before lockdown and fell by 31%–88% after lockdown, with the greatest reductions observed for coronary artery bypass grafts, carotid endarterectomy, aortic aneurysm repair and peripheral arterial disease procedures, compared with the previous year.	
Boeddinghaus, 2020	ACS admissions		220	178	Compared to January/February 2020, there was a dramatic reduction of ED presentations after the COVID-19 outbreak on March 1st (31% relative reduction). Comparing March/April 2020 to that of 2019, there was a 38.7% reduction in ED presentations	
Bromage, 2020	HF admissions	78		26	Significantly lower admission rate for HF was observed during the study covid-19 pandemic compared to all other included time periods.	Patients admitted during the COVID-19 pandemic had higher rates of NYHA III or IV symptoms and severe peripheral oedema
Bryndza, 2021	AMI admissions	1055		827	In comparison to the control period, there was a 21.6% decrease in the total number of AMI cases (a 18.6% decrease in the number of patients with STEMI and a 23.9% decrease in the number of patients with NSTEMI).	
Cammalleri, 2020	STEMI patients undergoing PCI	35		13	During March 2020, there was a 63% reduction of patients with STEMI admitted for PCI, when compared with the same period of 2019	Patients in 2020 had higher levels of cardiac biomarkers and a worse left ventricular ejection fraction at baseline

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Candelaresi, 2021	Stroke admissions				The global number of patients presenting with acute stroke did not significantly differ between the periods	Baseline NIHSS score was significantly more severe during the lockdown compared to the same period of 2019 and tended to be more severe compared to the immediate prelockdown phase
Chew, 2021	STEMI patients undergoing PCI		208	95	Fewer admissions during pandemic compared to pre-pandemic	
Choudhary, 2020	Cardiovascular emergencies (ACS, acute decompensated HF and high degree AV block)	1488	830	289	Fewer emergency cardiovascular admissions during the lockdown period than the pre-lockdown and pre-COVID periods.	Risk factors associated with poorer prognosis in ACS were higher in patients during the lockdown and pre-lockdown period compared to pre-COVID period.
Çinier, 2020	STEMI patients undergoing PCI	174		90	Significant reduction in STEMI cases during COVID-19 pandemic compared to previous year	
Colivicchi, 2020	Acute HF admissions	6060		2711	The number of patients with acute HF decreased by 49% during the pandemic period	Risk factors associated with poorer prognosis were higher in patients during the pandemic compared to the pre-COVID period
Cummings, 2020	Tele stroke consultations	5239		613	Fewer stroke patients were seen during the pandemic. The median number of weekly consults dropped from 112 to 77 during the pandemic. Black patients were less likely to present with strokes during the pandemic	
Del Pinto, 2020	CVDs admissions				Less cardiovascular hospitalizations occurred in 2020 than in 2019	
Enache, 2020	CVDs admissions	419		346	Compared to March 2019, the total cardiovascular admissions were lower by 17%. Similarly, compared to March 2019, cardiovascular emergency admissions were down by 21%.	
Erol, 2020	AMI admissions	1872		991	There was a 47.1% decrease in acute MI admissions during the pandemic. This reduction in admission was more prominent in patients with NSTEMI compared with STEMI	
Frisullo, 2020	Ischemic stroke admissions	41		52	No significant difference observed between 2019 and 2020 in number of admissions	

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Giannouchos, 2021	ED visits for medical conditions (included hypertension and diabetes)	Hypertension (461); diabetes (300)		Hypertension (251); diabetes (209)	Decrease in ED visits for both hypertension and diabetes	
Hoyer, 2020	Ischemic stroke admissions				A significant decrease in the number of admissions for transient ischemic attack was observed in 3 of 4 centers during the pandemic	
Hsiao, 2020	Stroke consultations				Compared with the 10 weeks prior, stroke consultations declined by 39% in the 5 weeks after announcement of COVID-19 mitigation measures. Results compared with the prior year and time trend analyses were consistent	
JF Huang, 2020	Tele stroke activations		142	71	There was a 50% reduction in stroke volume activations during the post-pandemic declaration period	
Ikenberg, 2020	Stroke referrals		171	70	The absolute daily number of Code Stroke referrals and the portion of patients with stroke mimics remained stable. The portion of female stroke patients decreased (55% to 33%; $p = 0.03$) during the lockdown.	Stroke severity as measured by the NIHSS increased during the lockdown.
Jasne, 2020	Stroke code activations	786		756	There was a significant decline in weekly stroke code volumes at the 3 hospitals from January to April, 2020. 30% decrease in total stroke codes during the pandemic weeks in 2020 versus 2019	There was no difference in stroke severity
John, 2020	Stroke admissions	148		210	There was a 41.9% increase in stroke admissions in 2020. The difference in 2020 was driven by significant increases in ischemic stroke, intracerebral hemorrhage and stroke mimics.	Ischemic stroke: Severity of stroke presentation was higher in 2020 as recorded by the NIHSS.
Kobo, 2020	STEMI patients undergoing PCI	136		107	There was a 22% decrease in STEMI admissions	Patients admitted in 2020 had higher admission and peak troponin levels
Kuitunen, 2020	ED visits and inpatient admissions for medical conditions (included AMI, strokes and other heart disease)		Stroke (553); AMI (650); other heart disease (1837)	Stroke (558); AMI (645); other heart disease (1513)	The visit rate and inpatient admissions due to AMI and strokes remained stable throughout the study period.	
Lauridsen, 2020	AMI admissions	AMI (11,769); AMI-CS (342)		AMI (2132); AMI-CS (60)	The total number of MI patients decreased by 15% during lockdown comparing the average number of MI admissions in 2015–2019 with the number of MIs in 2020	The incidence proportions of AMI-related cardiogenic shock were similar during lockdown comparing 2015–2019 and 2020
Little, 2020	STEMI admissions	440		348	There was a 21% reduction in STEMI admissions in 2020 vs in 2019	
Nagamine, 2020	Ischemic stroke admissions	68		48	There was reduction in stroke admissions in 2020 compared to 2019	

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Mitra, 2020	Acute stroke and AMI admissions	57		52	There was a 9.6% reduction in stroke and AMI admissions in 2020 compared to 2020	
Nguyen-Huynh, 2020	Acute stroke presentations		8337	783	Stroke volumes decreased significantly post lockdown compared with pre-lockdown	Post-lockdown patients had higher NIHSS scores, lower comorbidity score, and arrived more often by ambulance. Post-lockdown patients also had large vessel occlusions.
Oseran, 2020	Cardiovascular admissions				During the pandemic period, there was a decrease in admission rates for all conditions including cardiovascular conditions	
Paliwal, 2020	Stroke admissions		206	144	Decline in stroke activations	In terms of stroke severity, the median NIHSS on arrival was similar
Papafakis, 2020	ACS admissions	1077		771	ACS admissions in the COVID-19 period were reduced by 28.4% compared to 2019	During the COVID-19 period, patients admitted with ACS presented more frequently with left ventricular systolic impairment
Piuhola, 2020	STEMI admissions				During 2017–2019, there were no marked differences in STEMI incidence between January, February and March. During 2020, there was an average drop of 32% in STEMI incidence in March.	
Rashid Hons, 2020	AMI admissions with OHCA	731		524	AMI hospitalizations during COVID-19 period were reduced by >50%	
Richter, 2021	Stroke admissions				Decline in hospitalizations during the pandemic compared to the pre-pandemic period	
Rodríguez-Leor, 2020	STEMI admissions	1305		1009	Suspected STEMI patients treated in STEMI networks decreased by 27.6% with a reduction in confirmed STEMI cases by 22.7% during the pandemic	
Ruparelia, 2020	ACS admissions	376		280	There was a significant reduction in the entire spectrum of ACSs following the beginning of the COVID-19 pandemic	
Schirmer, 2020	Stroke admissions	320		163	In the COVID period in 2020, there was a drop in the absolute number of cases per calendar week	There was no difference in the severity of the presentation between groups
Seiffert, 2020	Admissions for AMI, acute limb ischemia, aortic rupture, stroke or TIA	78.6/100,000		70.6/100,000	Monthly admission rates declined from pre-COVID to COVID periods. The lowest admission rate was observed in April 2020	

Author, year of publication	Cardiometabolic condition	Historical control / pre-COVID-19 hospitalisations	Pre-pandemic / pre-lockdown hospitalisations	Pandemic / lockdown hospitalisations	Trends in hospitalisations for cardiometabolic outcomes	Severity of presentation
Sharma, 2020	Stroke and TIA admissions				There was a decline in stroke/TIA admissions and ED stroke alerts during 30 December 2019 to 19 April 2020. The greatest decline in hospital admissions was observed between 23 March and 19 April 2020	Baseline NIHSS score was higher in the pandemic period
Siegler, 2020	Stroke admissions		275	53	There was a mean fall of 38% in new stroke diagnoses	No difference with respect to severity of stroke
Tejada Meza, 2020	Stroke admissions		173/week	124/week	There was a decrease in the weekly mean admitted patients during the pandemic	
Uchino, 2020	Stroke presentations		10 alerts/day	8 alerts/day	There was a significant decrease in acute stroke presentations by 30% across emergency departments during the COVID-19 period	Stroke severity measured by NIHSS was unchanged.
Vensentini, 2020	CVDs admissions	Average (595)		Average (348)	The average number of CVD admissions decreased by 46.8% during the COVID-19 period. Reductions in cardiovascular surgery 72.3%, electrophysiological interventions 67.8%, NSTEMI 52.6%, angioplasties 47.6%, arrhythmias 48.7%, heart failure 46%, atrial fibrillation 35.7%, STEMI 34.7%, non cardiac chest pain 31.8% and others 51.6% during the COVID-19 period. Hypertensive crisis increased by 89%	
Wadhwa, 2021	CVD deaths		199,311	197,731	Deaths caused by ischemic heart disease and hypertensive disease increased nationally after the onset of the pandemic in 2020, compared with changes over the same period in 2019, but not for heart failure, cerebrovascular disease, or other diseases of the circulatory system.	
J Wang, 2020	Acute ischemic stroke admissions		320	255	There was a 22.1% and 39.5% decline in admission for acute ischemic stroke in April and May 2020, respectively.	Stroke severity at presentation measured by NIHSS was unchanged.
Yang, 2020	Acute stroke patients undergoing endovascular thrombectomy		34	21	Decline in acute stroke patients undergoing endovascular thrombectomy during the pandemic era	Stroke severity at presentation measured by NIHSS was unchanged.
Zhao, 2020	Stroke care				Hospital admissions related to stroke dropped by 40%	
Cox, 2020	Acute HF admissions				62% decrease in HF admissions during the pandemic period relative to last year	Severity at admission was unchanged

Table 3. Management, patient- and system-related delays and outcomes

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Araiza-Garaygordobil, 2021	Significant reduction of patients undergoing pPCI was observed (81.8% pre-pandemic vs. 76.2% pandemic, difference: -5.6%, $P=0.041$).				The proportion of patients who developed any mechanical complication during the pandemic period was higher when compared with the pre-pandemic period (1.98% [23/1161] vs. 0.98% [41/4143], $P=0.006$) and compared to the historical control (1.98% [23/1161] vs. 1.17% [30/2547], $P=0.057$).
Mafham, 2020	There were reductions in the number of PCI procedures for patients with both STEMI (438 PCI procedures per week in 2019 vs 346 by the end of March, 2020; percent reduction 21%) and NSTEMI (383 PCI procedures per week in 2019 vs 240 by the end of March, 2020; percent reduction 37%).			The median length of stay among patients with ACS fell from 4 days (IQR 2–9) in 2019 to 3 days (1–5) by the end of March, 2020.	No apparent change in in-hospital mortality among patients admitted with ACS in the period
Perrin, 2020		Delay from symptom onset to first medical contact was longer among patients suffering from STEMI in the COVID-19 period compared with the control period (112 min vs 60 min, $p = 0.049$). Delayed presentations were reported in 18.2% and 9% of patients in the COVID-19 and control periods, respectively ($p = 0.3$)	ACS patients delayed their call to the emergency services mainly because of fear of contracting or spreading COVID-19 following hospital admission, as well as of adding burden to the healthcare system	Hospital length of stay was significantly shorter for the COVID-19 period as compared to the control period (6 vs 7 days, $p = 0.03$).	
Tam, 2020		Delay from symptom onset to first medical contact was longer among patients suffering from STEMI in the COVID-19 period compared with the pre-pandemic period. The proportion of patients who presented out of the revascularization window during the pandemic period was higher when compared with the pre-pandemic period (33% vs 27.8%)			The primary composite outcome of in-hospital death, cardiogenic shock, sustained ventricular tachycardia or fibrillation and use of mechanical circulatory support was significantly higher during the pandemic period compared to pre-pandemic period (29.7% vs 14.1%, $p=0.02$)
Toniolo, 2020					
Huet, 2020					

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Kwok, 2020b		Compared with 2017–2019, patients admitted with primary PCI for STEMI in the month of April 2020 were more likely to have longer time from symptom-to-hospital (median 135 min vs 153 min, $p=0.004$) and they also had a longer door-to-balloon time (48 (21–112) vs 37 (16–94) min, $p<0.001$).		There was a shorter median length of stay postlockdown compared to prelockdown: 2 (1-3) days vs 3 (2-4) days, $p<0.001$).	No significant differences in in-hospital death and MACE were observed overall
Boukhris, 2020		There was increase in patients with >2 h delays in the setting of STEMI in the pandemic period compared to the same period in 2019. Delays in ischemic strokes were similar between the two periods			
Braiteh, 2020		In NSTEMI patients, 36.4% presented late (>24 hours of symptoms) during the COVID-19 pandemic in comparison with 2019 (27.1%, $P = .033$).			
Butt, 2020				Overall length of stay was shorter during the pandemic period compared to March 2019.	Deaths - Compared to March 2019 (179), there was 19% increase in in-hospital deaths in March 2020 (221) ($p=0.05$)
De Filippo, 2020					
De Rosa, 2020		Both patient- and system-related declared delays were substantially increased during the COVID-19 outbreak. Time from symptom onset to coronary angiography was increased by 39.2% in 2020 compared with the equivalent week in 2019, while the time from first medical contact to coronary revascularization was increased by 31.5%.			Case fatality rate during the pandemic was increased compared with 2019.
Fileti, 2020	Among those admitted for ACS, 57 (79.1%) were treated with PCI in 2020, and 67 (71.2%) in 2019, with an overall 14.9% reduction.	Among STEMI patients, the rate of those with a time delay presentation from symptoms onset longer than 180 min was significantly higher during the pandemic period compared to 2019			PCI procedural success and in-hospital mortality were not significantly different between the two periods
Folino, 2020					
Haddad, 2020		Longer delays between symptom onset and first medical contact were noted during the pandemic compared to pre-pandemic and control period			There were worse in-hospital outcomes (MACE, mechanical complications, death, other cardiac complications) during the pandemic compared to pre-pandemic and control period
Hauguel-Moreau, 2020		Median symptom-onset-to-first medical contact time was significantly higher in 2020 than in the two previous years (600 min [298–632] versus 121 min [55–291], $p < 0.001$). There was also a delay in STEMI management (3-fold increase in ischemic time)			
Holy, 2020					
Metzler, 2020					
Montagnon, 2021		For patients with ACS, the average time interval between the first symptoms and the consultation was shorter in 2020. However, the average time lapse between the consultation and subsequent cerebral imaging increased in 2020 compared with 2019.			

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Showkathali, 2020		The symptom to door time was prolonged in 2020 compared to 2019		The duration of hospital stay was longer in 2020 compared to previous years	There was no difference in in-hospital mortality between the two study periods of 2020 and 2019 respectively
Sokolski, 2020				The mean length of stay was significantly shorter in 2020 (4.9 days) in comparison to 2019 (5.9 days)	There was no statistically significant difference in death rates between studied periods: 107 (3.6%) in 2020 versus 175 (3.9%) deaths in 2019
Solomon, 2020					
Vacanti, 2020	The total number of coronary angiographies and PCIs were lower in 2020 compared to 2019 and 2019				
Yalamanchi, 2020					The in-hospital mortality of patients was also similar in all 3 years
Tsioufis, 2020					
Gasior, 2020					
Dreger, 2020	Number of PCI in AMI patients also fell.				
Anderson, 2020					
Gluckman, 2020				Median length of stay for patients with AMI was shorter in the early COVID-19 period by 7 hours and in the later COVID-19 period by 6 hours compared with the before period. Similar trends were observed for STEMI and NSTEMI	Patients with STEMI had a statistically greater risk of mortality during the later COVID-19 period
Mohammad, 2020	PCI was equally performed during the two periods	Time from symptom onset to PCI was shorter during the pandemic compared to the control period			No differences in all-cause mortality rates between the two periods
Piccolo, 2020					
Secco, 2020		Longer door-to-balloon and symptoms to PCI times in 2020 compared to 2019			No difference in in-hospital mortality between the two periods. However, in 2020, patients had a lower discharged residual left ventricular function and an increased predicted late cardiovascular mortality

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Ayad, 2021		Time from first medical contact to needle was longer during the pandemic period.		Hospital length of stay was longer during the pandemic	In-hospital mortality, incidence of re-infarction and need for revascularization were higher during the pandemic period. Incidence of HF, stroke and bleeding was not different between the periods
Bhatt, 2020				Hospital length of stay was shorter in March 2020: 4.8 (2.4-8.3) days compared with March 2019: 6.0 (3.1-9.6) days	In-hospital mortality was not significantly different between the two periods
Daoulah, 2021		Timing from the onset of symptoms to the balloon of more than 12 hours was higher during 2020 comparing to pre-COVID 19		No differences in length of hospital stay	There were no differences with respect to in-hospital events (mortality, thrombosis, bleeding etc)
Desai, 2020	Number of patients undergoing endovascular thrombectomy remained constant				
Diegoli, 2020	No differences in number of patients provided with reperfusion therapies	No differences in time from onset to admission.			
Gitt, 2020					
Hammad, 2020		Door-to-balloon time were not significantly different	(i) Fear of contracting COVID-19 (27%); (ii) Symptoms were COVID-19 related (18%); (iii) Did not want to burden the emergency dept (9%)	Shorter ICU duration and length of stay during the pandemic period: 2.3 vs 3.6 days	
Kerleroux, 2020		There was a significant increase in delays between imaging and groin puncture during the pandemic period			No difference in outcomes (successful reperfusion and in-hospital mortality)
Montaner, 2020		Time from symptoms onset to arrival at hospital was delayed during the pandemic period. Door-to-needle time was delayed during the pandemic. However, mean times of arrival to thrombectomy reference center from symptoms onset improved during the pandemic			
Neves Briard, 2020		Time from symptom onset to hospital presentation was longer during the pandemic period. Door-to-needle and door-to-recanalization metrics were also longer during the pandemic. A significantly smaller proportion of ischemic stroke patients was treated with thrombolysis or thrombectomy during the pandemic			

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Pop, 2020	There were 33.3% fewer acute revascularization treatments, 40.9% less intravenous thrombolysis and 27.6% less mechanical thrombectomy in 2020	No significant differences in patient- and system-related delays.			
Popovic, 2020		Delayed hospital presentation in the pandemic period compared to control period			Higher in-hospital mortality in the pandemic period
Range, 2020		Time from symptom onset to first medical contact was longer for lockdown group		Length of hospital stay was similar in both periods	There were higher rates of in-hospital MACE and mortality in the lockdown group but the differences were not significant.
Reinstadler, 2020		Door-to-balloon times were constant during the period. Total ischemic times increased from 164 min (calendar week 9/10) to 237 min (calendar week 11/12) and to 275 min (calendar week 13/14) ($p = 0.006$).			Rates of in-hospital death and re-infarction were similar between groups
Sarfo, 2020					Case fatality rate during the pandemic was increased compared with 2019.
Teo, 2020		Stroke onset-to-door arrival time was longer during the pandemic. There were no significant differences in the ambulance scene arrival to hospital arrival time, proportion of patients receiving reperfusion therapy, door-to-needle time, and mechanical thrombectomy procedural times during the 2 periods			
Toner, 2020		Symptom-to-door time was longer during the COVID-19 period (4-fold increase). Proportion of patients presenting late was also higher during the pandemic period.			
Abdelaziz, 2020		Delay in symptom-to-first medical contact during pandemic vs pre-COVID era. The door-to-balloon time was similar between both groups.			
Agarwal, 2020		The time from symptom onset to presentation was not significantly different the two groups. There were longer median door to head CT and door to groin puncture times during the pandemic compared to pre-pandemic times. Time to alteplase administration, door to reperfusion times and defect-free care were similar in the pandemic and pre-pandemic groups		There was no difference in the length of hospital stay between the pandemic and pre-pandemic cohorts	Successful recanalization rates were similar between the two groups. Pandemic patients had increased discharge mortality in multivariable analysis compared to pre-pandemic patients
Burgos, 2020					
Aldujeli, 2020		NSTEMI: The median pain-to-door time was longer during the pandemic compared to pre-pandemic era. There was a significant delay in door-to-reperfusion time during the pandemic. There were 24 (80%) and 25 (42%) patients who presented after 12 h of pain onset in pandemic and pre-pandemic eras, respectively ($P = 0.0006$). STEMI: The median pain-to-door time during the pandemic was longer than that of the pre-pandemic. There were 22 (47%) and 14 (24%) patients who presented after 12 h of pain onset in the pandemic and prepandemic eras, respectively ($P = 0.0127$). There was no difference in delay in door-to-reperfusion time.		There were no differences in length of hospitalization between pandemic and pre-pandemic eras.	There were no differences in in-hospital death, or stroke between pandemic and pre-pandemic eras.

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Andersson, 2020					Mortality was similar before and after the national lockdown for the population with HF
Ball, 2020					
Boeddinghaus, 2020	220/398 PCIs (55.3%) PCIs were performed before versus 178/398 PCIs (44.7%) after the outbreak.	Time from chest pain onset to ED presentation, postinfarction LVEF, and median door-to-balloon time remained unchanged.			
Bromage, 2020	There were no differences in inpatient management, including place of care and pharmacological management of heart failure with reduced ejection fraction				In-hospital mortality rates were low in both periods
Bryndza, 2021		There was a significant increase (90.7%) in the number of patients who experienced pain longer than 12 hours prior to presentation to the hospital			There was a 100% increase in mechanical complications during pandemic period compared to control period
Cammalleri, 2020		In March 2020, there was longer median time in symptom-to-first medical contact, spoke-to-hub, and the cumulative symptom-to-wire delay compared to March 2019		Length of hospitalization was longer in 2020	Procedural data and in-hospital outcomes were similar between the 2 groups. Patients in 2020 had a worse left ventricular ejection fraction at discharge.
Candelaresi, 2021	Compared to the pre-lockdown, there was a significant reduction in the number of acute reperfusion treatments for stroke.	The time to reach medical attention was significantly longer in the lockdown phase. For patients who underwent acute reperfusion treatment, there was a significantly longer time-to-imaging and a trend to longer time-to-needle (75 versus 90 min P 0.23), but not time-to-groin.			Discharge neurological status was not significantly different between the periods
Chew, 2021		Fewer patients in the pandemic group achieved door-to-balloon time <90 min compared with the pre-pandemic group.		There was no difference in hospital admission duration between groups.	In-hospital mortality was similar between groups. The 30-day readmission rate was lower in the pandemic group compared with the pre-pandemic group. The rates of sepsis and acute mitral regurgitation were higher in the pandemic group compared with the pre-pandemic group.

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Choudhary, 2020	Percentage of STEMI patients undergoing emergent catheterisation was lower in the lockdown and pre-lockdown period compared to pre-COVID period. Percentage of STEMI patients having thrombolysis was higher in the lockdown and pre-lockdown period compared to pre-COVID period.	The percentage of STEMI patients who presented outside the window period (presentation after 12 hours of symptom onset) was 6.1% in the pre-COVID period, 17.4% during the pre-lockdown period and 25.0% during the lockdown period.			In-hospital mortality was 7.3%, 3.5% and 2.7%, in the lockdown, pre-lockdown, and pre-COVID periods, respectively.
Çinier, 2020		Prolonged ischemic time, longer pain-to-balloon and door-to-balloon time during the pandemic.			
Colivicchi, 2020					In-hospital all-cause mortality was 17.2% in 2020 and 6.3% in 2019
Cummings, 2020	There was a higher percentage of patients receiving intravenous tPA during the pandemic, and the number of thrombectomies per week was lower during the pandemic	No differences in door-to-needle and door-in-door-out times			No differences in in-hospital mortality
Del Pinto, 2020	Less daily cardiovascular procedures performed in 2020 than in 2019				More in-hospital cardiovascular deaths occurred in 2020 compared with 2019. Less in-hospital all-cause mortality occurred in 2020 than 2019
Enache, 2020					
Erol, 2020	There was a significant reduction in the overall frequency of coronary angiography during the pandemic period compared to the pre-pandemic period. Frequency of PCI decreased during the pandemic.	EMS transport significantly increased during the pandemic period. Median time from symptom-onset to hospital-arrival was increased during the pandemic. The total ischemic time for patients with STEMI who were treated with PCI was significantly longer during the pandemic period compared with the pre-pandemic period. Door-to-balloon time was similar in the two periods.			In-hospital major adverse cardiac events were significantly increased during the pandemic period
Frisullo, 2020	Significant reduction of the total number of thrombolysis and a non-significant increase of thrombectomy during the pandemic	Significant increase in onset-to-door time and door-to-groin time during pandemic		Significant reduction in length of hospitalization during pandemic	
Giannouchos, 2021					
Hoyer, 2020	There was a significant drop in the thrombolysis rate by 60% and in the thrombectomy rate by 61% during the pandemic in one of the centers				

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Hsiao, 2020	Reperfusion treatments also appeared to decline by 31% and specifically thrombolysis by 33%				
JF Huang, 2020	Recommendation for acute stroke intervention (IV-tPA and/or thrombectomy) occurred at a lower rate for our postpandemic declaration group	The last known normal/symptom onset time to telestroke activation in the ED was significantly shorter for the postpandemic declaration group			
Ikenberg, 2020	There was no difference of daily numbers of patients receiving thrombolysis and thrombectomy				
Jasne, 2020	No difference in rate of Thrombolysis in Cerebral Infarction 2b or greater revascularization	There was no difference in time to presentation, door-to-needle and door-to-reperfusion times		No difference in median length of stay	There was no difference in discharge modified Rankin Scale.
John, 2020	Ischemic stroke: The rate of treatment with intravenous thrombolysis was similar in both years; Haemorrhagic stroke: Surgical treatment including placement of an external ventricular drain, endovascular embolization and microsurgical clipping/resection or hematoma evacuation occurred at similar rates.	Ischemic stroke: Presentation to the hospital from last known well time and door-to-needle times for intravenous thrombolysis was similar. However, door-to-groin puncture times for endovascular thrombectomy was significantly longer in 2020.			There was no difference in in-hospital mortality, discharge disposition or discharge/30-day modified Rankin Score
Kobo, 2020		Patients admitted in 2020 had greater likelihood of door-to-balloon times > 90 min and greater likelihood of pain-to-balloon times > 12 hours		Patients admitted in 2020 had longer hospital stay	Patients admitted in 2020 experienced higher rates hemodynamic instability and fewer early (<72 hours) discharge
Kuitunen, 2020					
Lauridsen, 2020	The proportion of patients who underwent CAG, PCI, CABG, and extra corporeal membrane oxygenation (ECMO) were similar between 2015 and 2019 and 2020 during lockdown				No difference in 7-day mortality was observed between study periods.
Little, 2020	Aspiration thrombectomy and rates of cases completed with TIMI flow less than 3 were similar between both groups	There was no significant difference in pain to first call for help or door-to-balloon. There was longer ambulance response times in 2020 than in 2019.		Length of stay was similar	There was no significant difference in ICU admission or in-hospital all-cause mortality

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Nagamine, 2020		The average last known well to arrival time for stroke codes was longer in 2020 than in 2019. Mean time from patient arrival to administration of tPA (door-to-needle) was similar for both periods. Mean time from patient arrival to vessel puncture for endovascular therapy (door to puncture) was shorter in 2020 compared to 2019.			In-hospital mortality was higher in 2020 than in 2019
Mitra, 2020		Median time from symptom onset to presentation was shorter in 2020 compared to 2019. Proportion of patients who presented >12h after onset of symptoms were similar in both periods. Median time to primary reperfusion intervention was longer in 2020 compared to 2019.		No differences in hospital length of stay	There were no differences in mortality at hospital discharge
Nguyen-Huynh, 2020	The percentage of patients receiving alteplase was not significantly different.	Median door-to-needle time among noncanceled stroke alerts was unchanged. The median times from LTKW-to-needle time or alteplase treatment time were not significantly different.		Length of stay was similar	Stroke discharges decreased significantly post lockdown compared with pre-lockdown. No difference in in-hospital mortality
Oseran, 2020					
Paliwal, 2020	Proportion of activations receiving acute recanalization therapy remained stable.	In patients undergoing acute intervention, door-to-activation and door-to-neurologist review time were longer during the lockdown compared to pre-lockdown. Symptom-to-door-time was similar			For patients that received acute recanalization therapy, early neurological outcomes in terms of change in median NIHSS at 24 h were largely similar
Papafaklis, 2020					There was no difference in the rate of cardiac deaths between the two periods, while the rates of in-hospital repeat MI and stent thrombosis were numerically higher during the COVID-19
Piuhola, 2020					
Rashid Hons, 2020	The overall rates of invasive coronary angiography were significantly lower during COVID-19 period. The use of PCI was also lower across COVID-19 months in 2020 compared with pre-COVID-19 months in 2019. Patients admitted during the COVID-19 period were slightly less likely to be seen by a cardiologist	Increased time to reperfusion in STEMI patients during the COVID-19 period			Increased in-hospital mortality during the COVID-19 period
Richter, 2021	IVT rate in patients with stroke was comparable, whereas mechanical thrombectomy rate was significantly higher during the pandemic				In-hospital mortality was significantly increased in patients with stroke during the pandemic period
Rodríguez-Leor, 2020	There were no differences in reperfusion strategy (> 94% treated with primary PCI in both groups)	Patients treated with primary PCI during the COVID-19 outbreak had a longer ischemic time but showed no differences in the time from first medical contact to reperfusion.			In-hospital mortality was higher during the COVID-19 period

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Ruparelia, 2020					
Schirmer, 2020		The mean interval from last-known-well to the presentation was significantly longer in the COVID period			
Seiffert, 2020	The percentage of patients treated with interventional or open-surgical procedures remained similar over time				In-hospital mortality in hospitalizations for stroke increased from pre-COVID to COVID
Sharma, 2020		There was no difference in time from symptom onset to hospital arrival.			
Siegler, 2020	Fewer brain MRIs were performed during the COVID-19 period when compared to pre-COVID-19	There was no significant delay from the time patients were last known well to ED arrival, arrival to computed tomography scan or to thrombolysis.		Patients treated during COVID-19 had a shorter hospital length of stay when compared to patients admitted during the pre-COVID-19 period: 2.5 (2-7) vs 4 (2-8)	No difference in in-hospital mortality
Tejada Meza, 2020	There were no differences in the proportion of patients undergoing intravenous and endovascular treatments procedures				In-hospital mortality of stroke patients increased significantly
Uchino, 2020	Thrombolysis decreased during the COVID-19 period but thrombectomy remained unchanged	Time to presentation and time to treatment were unchanged. Door-to-needle, CT completion and puncture times were unchanged.			
Vensentini, 2020					
Wadhera, 2021					
J Wang, 2020	Patients admitted during the COVID-19 pandemic were more likely to undergo intravenous thrombolysis and mechanical thrombectomy				There were no differences in patients' disposition including home, short-term, and long-term facility
Yang, 2020		Onset to hospital arrival was not different. The time from hospital arrival to puncture and time from hospital arrival to reperfusion were significantly prolonged in the pandemic group compared with the pre-pandemic group.			The rate of successful reperfusion was not significantly different between the two groups

Author, year of publication	Management	Patient- and system-related delays	Reasons for delays in seeking medical care	Length of stay	Outcomes related to management
Zhao, 2020	The total number of thrombolysis and thrombectomy cases dropped by 26.7% and 25.3%, respectively, in 2020		Patients' and their families' fear of contracting virus in hospital (87.2%); Insufficient transportation resources (43.2%); Lack of first aid knowledge (42.3%); Lack of family support (31.7%); Insufficient ambulance resources (15.4%)		
Cox, 2020				No difference in length of stay	In-hospital mortality rate was not different between the two periods

Figures

Figure 1

Selection of studies included in the review

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryfile.docx](#)